Have your own idea? Try our Stock Screener
Chinese (SSE) Pharma Industry Analysis
UpdatedAug 10, 2025
DataAggregated Company Financials
Companies217
- 7D-1.6%
- 3M19.8%
- 1Y35.0%
- YTD27.6%
The Pharma industry is down 1.6% over the last week with Asymchem Laboratories (Tianjin) the worst performer, down 12%. Meanwhile, BrightGene Bio-Medical Technology actually outperformed within the industry, gaining 16% in the last week. This takes the industry's 12 month performance to a gain of 35%. Looking forward, earnings are forecast to grow by 14% annually.
Industry Valuation and Performance
Has the Chinese Pharma Industry valuation changed over the past few years?
| Date | Market Cap | Revenue | Earnings | PE | Absolute PE | PS |
|---|---|---|---|---|---|---|
| Sun, 10 Aug 2025 | CN¥3.2t | CN¥780.6b | CN¥71.6b | 34.9x | 45x | 4.1x |
| Tue, 08 Jul 2025 | CN¥2.9t | CN¥780.0b | CN¥71.3b | 32.6x | 40.7x | 3.7x |
| Thu, 05 Jun 2025 | CN¥2.9t | CN¥781.2b | CN¥71.5b | 33.7x | 40.9x | 3.7x |
| Sat, 03 May 2025 | CN¥2.6t | CN¥789.9b | CN¥71.9b | 29.3x | 36.6x | 3.3x |
| Mon, 31 Mar 2025 | CN¥2.6t | CN¥798.3b | CN¥77.0b | 29.8x | 34.2x | 3.3x |
| Wed, 26 Feb 2025 | CN¥2.5t | CN¥800.1b | CN¥75.7b | 28.6x | 33.1x | 3.1x |
| Fri, 24 Jan 2025 | CN¥2.5t | CN¥799.8b | CN¥75.6b | 27.1x | 32.5x | 3.1x |
| Sun, 22 Dec 2024 | CN¥2.7t | CN¥799.8b | CN¥75.6b | 31.2x | 35.2x | 3.3x |
| Tue, 19 Nov 2024 | CN¥2.6t | CN¥799.8b | CN¥75.6b | 29.2x | 34.7x | 3.3x |
| Thu, 17 Oct 2024 | CN¥2.6t | CN¥798.5b | CN¥76.2b | 28.4x | 33.6x | 3.2x |
| Sat, 14 Sep 2024 | CN¥2.2t | CN¥798.6b | CN¥76.3b | 24.6x | 29.1x | 2.8x |
| Mon, 12 Aug 2024 | CN¥2.4t | CN¥805.2b | CN¥76.4b | 27.7x | 31x | 2.9x |
| Wed, 10 Jul 2024 | CN¥2.3t | CN¥804.7b | CN¥76.5b | 28.3x | 30.2x | 2.9x |
| Fri, 07 Jun 2024 | CN¥2.5t | CN¥805.6b | CN¥74.6b | 27.7x | 34x | 3.1x |
| Sun, 05 May 2024 | CN¥2.7t | CN¥821.4b | CN¥77.5b | 31.3x | 35.2x | 3.3x |
| Tue, 02 Apr 2024 | CN¥2.6t | CN¥828.7b | CN¥78.3b | 28.6x | 33.6x | 3.2x |
| Thu, 29 Feb 2024 | CN¥2.5t | CN¥832.2b | CN¥80.8b | 25.3x | 31.2x | 3x |
| Sat, 27 Jan 2024 | CN¥2.5t | CN¥830.7b | CN¥79.8b | 27.7x | 31.9x | 3.1x |
| Mon, 25 Dec 2023 | CN¥2.8t | CN¥827.7b | CN¥79.7b | 29.7x | 34.6x | 3.3x |
| Wed, 22 Nov 2023 | CN¥2.9t | CN¥820.0b | CN¥78.7b | 31.6x | 36.5x | 3.5x |
| Fri, 20 Oct 2023 | CN¥2.7t | CN¥825.0b | CN¥78.6b | 30.3x | 33.9x | 3.2x |
| Sun, 17 Sep 2023 | CN¥2.7t | CN¥824.6b | CN¥78.5b | 31x | 34.5x | 3.3x |
| Tue, 15 Aug 2023 | CN¥2.7t | CN¥814.6b | CN¥78.0b | 32.3x | 34.9x | 3.3x |
| Thu, 13 Jul 2023 | CN¥2.8t | CN¥810.5b | CN¥76.7b | 30.8x | 36.3x | 3.4x |
| Sat, 10 Jun 2023 | CN¥2.9t | CN¥809.6b | CN¥76.3b | 33.1x | 37.5x | 3.5x |
| Mon, 08 May 2023 | CN¥3.0t | CN¥809.6b | CN¥76.8b | 35.2x | 39x | 3.7x |
| Wed, 05 Apr 2023 | CN¥2.9t | CN¥794.4b | CN¥88.4b | 33.9x | 32.9x | 3.7x |
| Fri, 03 Mar 2023 | CN¥3.0t | CN¥777.4b | CN¥83.3b | 37.6x | 35.5x | 3.8x |
| Sun, 29 Jan 2023 | CN¥2.9t | CN¥771.3b | CN¥83.2b | 35.3x | 35x | 3.8x |
| Tue, 27 Dec 2022 | CN¥2.7t | CN¥771.4b | CN¥82.1b | 34.5x | 32.9x | 3.5x |
| Thu, 24 Nov 2022 | CN¥2.8t | CN¥767.8b | CN¥81.9b | 37x | 33.7x | 3.6x |
| Sat, 22 Oct 2022 | CN¥2.6t | CN¥760.6b | CN¥83.0b | 33.8x | 31.8x | 3.5x |
| Mon, 19 Sep 2022 | CN¥2.4t | CN¥759.9b | CN¥79.3b | 30x | 30.7x | 3.2x |
| Wed, 17 Aug 2022 | CN¥2.7t | CN¥756.0b | CN¥81.7b | 31.5x | 32.6x | 3.5x |
Price to Earnings Ratio
32.6x
Current Industry PE
- Investors are optimistic on the Chinese Pharmaceuticals industry, and appear confident in long term growth rates.
- The industry is trading at a PE ratio of 45.0x which is higher than its 3-year average PE of 34.5x.
- The 3-year average PS ratio of 3.4x is lower than the industry's current PS ratio of 4.1x.
Past Earnings Growth
- The earnings for companies in the Pharmaceuticals industry have declined 4.3% per year over the last three years.
- Meanwhile revenues have remained mostly flat.
- This means that although sales have remained flat, either the cost of doing business or the level of investment back into businesses has increased, which has decreased profits.
Industry Trends
Which industries have driven the changes within the Chinese Healthcare industry?
| CN Market | 1.94% | |
| Healthcare | -0.84% | |
| Pharma | -1.57% | |
| Pharma | -1.57% | |
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.
Top Stock Gainers and Losers
Which companies have driven the market over the last 7 days?
| Company | Last Price | 7D | 1Y | Valuation | |
|---|---|---|---|---|---|
| 688166 BrightGene Bio-Medical Technology | CN¥114.83 | 15.7% +CN¥6.6b | 346.6% | PE351.3x | |
| 002653 Haisco Pharmaceutical Group | CN¥59.46 | 10.4% +CN¥6.2b | 105.0% | PE188.4x | |
| 300199 Hybio Pharmaceutical | CN¥23.74 | 17.1% +CN¥3.1b | 148.3% | PS28x | |
| 300436 Fujian Cosunter Pharmaceutical | CN¥118.90 | 16.2% +CN¥2.6b | 561.7% | PS45.2x | |
| 002020 Zhejiang Jingxin Pharmaceutical | CN¥19.12 | 16.2% +CN¥2.2b | 78.7% | PE22.4x |